Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Baylor College of Medicine
mi
from
Houston, TX
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Children's Hospital of Alabama
mi
from
Birmingham, AL
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Children's Hospital of Orange County
mi
from
Orange, CA
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Childrens National Medical Center
mi
from
Washington,
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Columbia University Medical Center
mi
from
New York, NY
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Oregon Health and Science University
mi
from
Portland, OR
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Riley Hospital for Children
mi
from
Indianapolis, IN
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Saint Jude Childrens Research Hospital
mi
from
Memphis, TN
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Saint Jude Childrens Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Seattle Children's Hospital
mi
from
Seattle, WA
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
University of Minnesota Cancer Center-Fairview
mi
from
Minneapolis, MN
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
University of Minnesota Cancer Center-Fairview
mi
from
Minneapolis, MN
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
University of California San Francisco Medical Center-Parnassus
mi
from
San Francisco, CA
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
University of California San Francisco Medical Center-Parnassus
mi
from
San Francisco, CA
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Washington University School of Medicine
mi
from
St. Louis, MO
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant
A Phase 2 Trial of Carfilzomib Consolidation After Autologous Stem Cell Transplantation for Multiple Myeloma(CARAMEL 2)
Status: Enrolling
Updated:  1/7/2016
Washington University School of Medicine
mi
from
Saint Louis, MO
Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant
A Phase 2 Trial of Carfilzomib Consolidation After Autologous Stem Cell Transplantation for Multiple Myeloma(CARAMEL 2)
Status: Enrolling
Updated: 1/7/2016
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant
A Phase 2 Trial of Carfilzomib Consolidation After Autologous Stem Cell Transplantation for Multiple Myeloma(CARAMEL 2)
Status: Enrolling
Updated:  1/7/2016
City of Hope
mi
from
Duarte, CA
Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant
A Phase 2 Trial of Carfilzomib Consolidation After Autologous Stem Cell Transplantation for Multiple Myeloma(CARAMEL 2)
Status: Enrolling
Updated: 1/7/2016
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant
A Phase 2 Trial of Carfilzomib Consolidation After Autologous Stem Cell Transplantation for Multiple Myeloma(CARAMEL 2)
Status: Enrolling
Updated:  1/7/2016
The Mayo Clinic
mi
from
Rochester, MN
Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant
A Phase 2 Trial of Carfilzomib Consolidation After Autologous Stem Cell Transplantation for Multiple Myeloma(CARAMEL 2)
Status: Enrolling
Updated: 1/7/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Phase II Study of Pentostatin With Cyclophosphamide and Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  1/7/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Phase II Study of Pentostatin With Cyclophosphamide and Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 1/7/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
A Pilot, Pharmacodynamic Correlate, Multi-Institutional Trial of Sirolimus in Combination With Chemotherapy (Mitoxantrone, Etoposide, Cytarabine) for the Treatment of High Risk, Acute Myelogenous Leukemia
Status: Enrolling
Updated:  1/8/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
A Pilot, Pharmacodynamic Correlate, Multi-Institutional Trial of Sirolimus in Combination With Chemotherapy (Mitoxantrone, Etoposide, Cytarabine) for the Treatment of High Risk, Acute Myelogenous Leukemia
Status: Enrolling
Updated: 1/8/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
A Pilot, Pharmacodynamic Correlate, Multi-Institutional Trial of Sirolimus in Combination With Chemotherapy (Mitoxantrone, Etoposide, Cytarabine) for the Treatment of High Risk, Acute Myelogenous Leukemia
Status: Enrolling
Updated:  1/8/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
A Pilot, Pharmacodynamic Correlate, Multi-Institutional Trial of Sirolimus in Combination With Chemotherapy (Mitoxantrone, Etoposide, Cytarabine) for the Treatment of High Risk, Acute Myelogenous Leukemia
Status: Enrolling
Updated: 1/8/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias
A Phase I Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, in Patients With Advanced Leukemias
Status: Enrolling
Updated:  1/8/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias
A Phase I Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, in Patients With Advanced Leukemias
Status: Enrolling
Updated: 1/8/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients With Refractory Hematological Malignancies
Status: Enrolling
Updated:  1/8/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients With Refractory Hematological Malignancies
Status: Enrolling
Updated: 1/8/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients With Refractory Hematological Malignancies
Status: Enrolling
Updated:  1/8/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients With Refractory Hematological Malignancies
Status: Enrolling
Updated: 1/8/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Status: Enrolling
Updated:  1/8/2016
University of California at San Francisco
mi
from
San Francisco, CA
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Status: Enrolling
Updated: 1/8/2016
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Status: Enrolling
Updated:  1/8/2016
University of Maryland Medical Center
mi
from
Baltimore, MD
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Status: Enrolling
Updated: 1/8/2016
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Status: Enrolling
Updated:  1/8/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Status: Enrolling
Updated: 1/8/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Status: Enrolling
Updated:  1/8/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Status: Enrolling
Updated: 1/8/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Status: Enrolling
Updated:  1/8/2016
Cornell University
mi
from
New York, NY
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Status: Enrolling
Updated: 1/8/2016
Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab With or Without Concurrent Avastin® for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  1/11/2016
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab With or Without Concurrent Avastin® for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 1/11/2016
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab With or Without Concurrent Avastin® for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  1/11/2016
The Mayo Clinic
mi
from
Rochester, MN
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab With or Without Concurrent Avastin® for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 1/11/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Advanced Medical Specialties
mi
from
Miami, FL
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Advanced Medical Specialties
mi
from
Miami, FL
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Bay Area Cancer Research Dept.ofBayAreaCancerResearch
mi
from
Concord, CA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Bay Area Cancer Research Dept.ofBayAreaCancerResearch
mi
from
Concord, CA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Baylor Research Institute Baylor Research Institute (17)
mi
from
Dallas, TX
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Baylor Research Institute Baylor Research Institute (17)
mi
from
Dallas, TX
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Cancer Center of Kansas
mi
from
Witchita, KA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Cancer Center of Kansas
mi
from
Witchita, KA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Cancer Centers of the Carolinas Cancer Center
mi
from
Greenville, SC
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Cancer Centers of the Carolinas Cancer Center
mi
from
Greenville, SC
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Duke University Medical Center Duke University Med Ctr
mi
from
Durham, NC
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Duke University Medical Center Duke University Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Georgia Regents University MedCollege of GA Cancer Ctr 2
mi
from
Augusta, GA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Georgia Regents University MedCollege of GA Cancer Ctr 2
mi
from
Augusta, GA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Hackensack University Medical Center Dept.of HackensackUniv.MedCtr.
mi
from
Hackensack, NJ
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Hackensack University Medical Center Dept.of HackensackUniv.MedCtr.
mi
from
Hackensack, NJ
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Henry Ford Hospital
mi
from
Detroit, MI
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Indiana Blood and Marrow Institute
mi
from
Beach Grove, IN
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Indiana Blood and Marrow Institute
mi
from
Beach Grove, IN
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Louis A. Weiss Memorial Hospital
mi
from
Chicago, IL
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Louis A. Weiss Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center(3)
mi
from
New Orleans, LA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center(3)
mi
from
New Orleans, LA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Millennium Oncology
mi
from
Houston, TX
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Millennium Oncology
mi
from
Houston, TX
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Montefiore Medical Center
mi
from
Bronx, NY
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials